
--- Page 1 ---
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
www.fda.gov
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY AND INSTRUMENT
I Background Information:
A 510(k) Number
K192376
B Applicant
DiaSorin Molecular LLC
C Proprietary and Established Names
Simplexa VZV Swab Direct, Simplexa VZV Positive Control Pack
D Regulatory Information
Product Regulation
Classification Panel
Code(s) Section
21 CFR 866.3309 - Herpes
Virus Nucleic Acid-Based
PGI Class II Cutaneous And MI - Microbiology
Mucocutaneous Lesion
Panel
21 CFR 866.3920 -
Assayed quality control
PMN Class II MI - Microbiology
material for clinical
microbiology assays
II Submission/Device Overview:
A Purpose for Submission:
To obtain a substantial equivalence determination and FDA clearance for a new device.
B Measurand:
Varicella-zoster virus DNA
K192376 - Page 1 of 16

[Table 1 on page 1]
	Product		Classification		Regulation		Panel
	Code(s)				Section		
PGI			Class II	21 CFR 866.3309 - Herpes
Virus Nucleic Acid-Based
Cutaneous And
Mucocutaneous Lesion
Panel			MI - Microbiology
PMN			Class II	21 CFR 866.3920 -
Assayed quality control
material for clinical
microbiology assays			MI - Microbiology

--- Page 2 ---
C Type of Test:
Realtime Polymerase Chain Reaction
III Intended Use/Indications for Use:
A Intended Use(s):
See Indications for Use below.
B Indication(s) for Use:
Simplexa™ VZV Swab Direct
The DiaSorin Molecular Simplexa™ VZV Swab Direct assay is intended for use on the
LIAISON® MDX instrument for the qualitative detection of varicella-zoster virus (VZV) DNA
present in cutaneous and mucocutaneous lesion swabs from patients with signs and symptoms of
VZV infection. This test is intended as an aid in the diagnosis of VZV infection. Negative results
do not preclude VZV infection and should not be used as the sole basis for treatment or other
patient management decisions.
Simplexa™ VZV Positive Control Pack
The Simplexa™ VZV Positive Control Pack is intended to be used as a control with the
Simplexa™ VZV Direct kit and the Simplexa™ VZV Swab Direct kit on the LIAISON® MDX
instrument. It is not intended for use with other assays or systems.
C Special Conditions for Use Statement(s):
Rx - For Prescription Use Only
D Special Instrument Requirements:
LIAISON MDX instrument
IV Device/System Characteristics:
A Device Description:
The Simplexa VZV Swab Direct assay is a real-time PCR system that enables the direct
amplification and detection of VZV DNA from unprocessed cutaneous and mucocutaneous
lesion swab specimens without nucleic acid extraction. The system consists of the Simplexa
VZV Swab Direct assay, the LIAISON MDX (with LIAISON MDX Studio Software), the Direct
Amplification Disc (DAD) and associated accessories.
In the Simplexa VZV Swab Direct assay, fluorescent probes are used together with
corresponding forward and reverse primers to amplify VZV and internal control targets. A well-
K192376 - Page 2 of 16

--- Page 3 ---
conserved region of the VZV DNA polymerase gene is targeted to identify VZV DNA in the
specimen. An internal control is used to detect PCR failure and/or inhibition.
B Principle of Operation:
Nucleic acid amplification testing (NAAT)
C Instrument Description Information:
Modes of Operation Yes No
Does the applicant’s device contain the ability to transmit data to a computer,
webserver, or mobile device?
Does the applicant’s device transmit data to a computer, webserver, or mobile device
using wireless transmission?
Software
FDA has reviewed applicant’s Hazard Analysis and software development processes
for this line of product types.
1. Instrument Name: LIAISON MDX
2. Specimen Identification: N/A
3. Specimen Sampling and Handling: N/A
4. Calibration: N/A
5. Quality Control: N/A
V Substantial Equivalence Information:
A Predicate Device Name(s):
Solana HSV 1+2/VZV Assay
B Predicate 510(k) Number(s):
K162451
C Comparison with Predicate(s):
Device & Predicate
K192376 K162451
Device(s):
Device Trade Name Simplexa VZV Swab Direct Solana HSV 1+2/VZV Assay
General Device Characteristic Similarities
Intended Use/ The DiaSorin Molecular The Solana HSV 1+2/VZV
Indications for Use Simplexa VZV Swab Direct Assay is an in vitro diagnostic
K192376 - Page 3 of 16

[Table 1 on page 3]
	Modes of Operation			Yes			No	
Does the applicant’s device contain the ability to transmit data to a computer,
webserver, or mobile device?								
Does the applicant’s device transmit data to a computer, webserver, or mobile device
using wireless transmission?								
	Software							
FDA has reviewed applicant’s Hazard Analysis and software development processes
for this line of product types.								

[Table 2 on page 3]
	Device & Predicate		K192376	K162451	
	Device(s):				
Device Trade Name			Simplexa VZV Swab Direct	Solana HSV 1+2/VZV Assay	
	General Device Characteristic Similarities				
Intended Use/
Indications for Use			The DiaSorin Molecular
Simplexa VZV Swab Direct	The Solana HSV 1+2/VZV
Assay is an in vitro diagnostic	

--- Page 4 ---
assay is intended for use on test, using isothermal
the LIAISON MDX amplification technology
instrument for the (helicase-dependent
qualitative detection of amplification, HDA), for the
varicella-zoster virus qualitative detection and
(VZV) DNA present in differentiation of herpes simplex
cutaneous and virus type 1, herpes simplex
mucocutaneous lesion virus type 2, and varicella-zoster
swabs from patients with virus DNA isolated and purified
signs and symptoms of from cutaneous or
VZV infection. This test is mucocutaneous lesion samples
intended as an aid in the obtained from symptomatic
diagnosis of VZV infection. patients suspected of active
Negative results do not herpes simplex virus 1, herpes
preclude VZV infection and simplex virus 2 and/or
should not be used as the Varicella-zoster infection. The
sole basis for treatment or Solana HSV 1+2/VZV Assay is
other patient management intended to aid in the diagnosis
decisions. of herpes simplex virus 1, herpes
simplex virus 2 and varicella-
zoster virus active cutaneous or
mucocutaneous infections.
Negative results do not preclude
herpes simplex virus 1, herpes
simplex virus 2 and varicella-
zoster virus infections and
should not be used as the sole
basis for diagnosis, treatment or
other management decisions.
The Solana HSV 1+2/VZV
Assay is intended for use only
with the Solana instrument.
Automated
Yes Yes
System
Technology Nucleic acid amplification Same
General Device Characteristic Differences
Instrument LIAISON MDX Solana instrument
VI Standards/Guidance Documents Referenced:
N/A
VII Performance Characteristics (if/when applicable):
A Analytical Performance:
K192376 - Page 4 of 16

[Table 1 on page 4]
		assay is intended for use on
the LIAISON MDX
instrument for the
qualitative detection of
varicella-zoster virus
(VZV) DNA present in
cutaneous and
mucocutaneous lesion
swabs from patients with
signs and symptoms of
VZV infection. This test is
intended as an aid in the
diagnosis of VZV infection.
Negative results do not
preclude VZV infection and
should not be used as the
sole basis for treatment or
other patient management
decisions.	test, using isothermal
amplification technology
(helicase-dependent
amplification, HDA), for the
qualitative detection and
differentiation of herpes simplex
virus type 1, herpes simplex
virus type 2, and varicella-zoster
virus DNA isolated and purified
from cutaneous or
mucocutaneous lesion samples
obtained from symptomatic
patients suspected of active
herpes simplex virus 1, herpes
simplex virus 2 and/or
Varicella-zoster infection. The
Solana HSV 1+2/VZV Assay is
intended to aid in the diagnosis
of herpes simplex virus 1, herpes
simplex virus 2 and varicella-
zoster virus active cutaneous or
mucocutaneous infections.
Negative results do not preclude
herpes simplex virus 1, herpes
simplex virus 2 and varicella-
zoster virus infections and
should not be used as the sole
basis for diagnosis, treatment or
other management decisions.
The Solana HSV 1+2/VZV
Assay is intended for use only
with the Solana instrument.	
Automated
System		Yes	Yes	
Technology		Nucleic acid amplification	Same	
	General Device Characteristic Differences			
Instrument		LIAISON MDX	Solana instrument	

--- Page 5 ---
1. Precision/Reproducibility:
Reproducibility for the Simplexa VZV Swab Direct assay was evaluated at three (3)
investigative sites to assess the device's inter-site, inter/intra-day and inter/intra-assay
reproducibility. Each of the laboratories tested a sample panel consisting of Simplexa VZV
Swab Direct Positive Control, No Template Control, and four (4) contrived samples in
negative matrix. Two (2) strains of VZV were used in the study, 9939 and Ellen. The four (4)
contrived samples consisted of a low positive (LP) at 2x LoD and a medium positive (MP) at
4x LoD for each VZV strain. Each sample panel member was tested in triplicate per run, for
two (2) runs per day by two (2) different operators at each site. Therefore, a total of ninety
(90) replicates [three (3) replicates x two (2) runs x five (5) days x three (3) sites] were tested
for each sample panel member. A total of six (6) LIAISON MDX instruments [two (2) per
site] were used. The combined results for all sites are presented in Table 1.
Table 1. Simplexa VZV Swab Direct Reproducibility
Summary of VZV Qualitative Results and VZV Ct Values ± SD (%CV)
Site 1 Site 2 Site 4 All Sites
% % % %
Agreement Detected Agreement Detected Agreement Detected Agreement Detected
Sample With Mean Ct ± With Mean Ct ± With Mean Ct ± With Mean Ct ±
Expected SD (%CV) Expected SD (%CV) Expected SD (%CV) Expected SD (%CV)
Results Results Results Results
100.0% 36.6 ± 1.12 100.0% 36.8 ± 0.68 100.0% 36.4 ± 0.83 100.0% 36.6 ± 0.9
9939 LP
(30/30) (3.1%) (30/30) (1.9%) (30/30) (2.3%) (90/90) (2.5%)
100.0% 35.8 ± 0.86 100.0% 35.7 ± 0.54 100.0% 35.3 ± 0.78 100.0% 35.6 ± 0.76
9939 MP
(30/30) (2.4%) (30/30) (1.5%) (30/30) (2.2%) (90/90) (2.1%)
100.0% 35.4 ± 1.22 100.0% 34.5 ± 1.77 100.0% 35.0 ± 0.56 100.0% 35.0 ± 1.32
Ellen LP
(30/30) (3.4%) (30/30) (5.1%) (30/30) (1.6%) (90/90) (3.8%)
100.0% 34.5 ± 0.65 100.0% 34.5 ± 0.47 100.0% 33.5 ± 1.3 100.0% 34.1 ± 0.99
Ellen MP
(30/30) (1.9%) (30/30) (1.4%) (30/30) (3.9%) (90/90) (2.9%)
UTM 0.0% 0.0 ± 0.00 0.0% 0.0 ± 0.00 0.0% 0.0 ± 0.00 0.0% 0.0 ± 0.00
(NTC) (0/30) (N/A) (0/30) (N/A) (0/30) (N/A) (0/90) (N/A)
100.0% 30.2 ± 0.74 100.0% 30.4 ± 0.59 100.0% 29.7 ± 0.86 100.0% 30.1 ± 0.79
PC
(30/30) (2.5%) (30/30) (1.9%) (30/30) (2.9%) (90/90) (2.6%)
2. Linearity: N/A
3. Analytical Specificity/Interference:
Cross-Reactivity (Analytical Specificity): The Simplexa VZV Swab Direct assay’s analytical
specificity was evaluated by testing the ability of the assay to exclusively identify VZV with no
cross-reactivity to organisms that are closely related, cause similar clinical symptoms or that
K192376 - Page 5 of 16

[Table 1 on page 5]
Summary of VZV Qualitative Results and VZV Ct Values ± SD (%CV)								
	Site 1		Site 2		Site 4		All Sites	
								
	%		%		%		%	
	Agreement	Detected	Agreement	Detected	Agreement	Detected	Agreement	Detected
Sample	With	Mean Ct ±	With	Mean Ct ±	With	Mean Ct ±	With	Mean Ct ±
	Expected	SD (%CV)	Expected	SD (%CV)	Expected	SD (%CV)	Expected	SD (%CV)
	Results		Results		Results		Results	
								
9939 LP	100.0%
(30/30)	36.6 ± 1.12
(3.1%)	100.0%
(30/30)	36.8 ± 0.68
(1.9%)	100.0%
(30/30)	36.4 ± 0.83
(2.3%)	100.0%
(90/90)	36.6 ± 0.9
(2.5%)
9939 MP	100.0%
(30/30)	35.8 ± 0.86
(2.4%)	100.0%
(30/30)	35.7 ± 0.54
(1.5%)	100.0%
(30/30)	35.3 ± 0.78
(2.2%)	100.0%
(90/90)	35.6 ± 0.76
(2.1%)
Ellen LP	100.0%
(30/30)	35.4 ± 1.22
(3.4%)	100.0%
(30/30)	34.5 ± 1.77
(5.1%)	100.0%
(30/30)	35.0 ± 0.56
(1.6%)	100.0%
(90/90)	35.0 ± 1.32
(3.8%)
Ellen MP	100.0%
(30/30)	34.5 ± 0.65
(1.9%)	100.0%
(30/30)	34.5 ± 0.47
(1.4%)	100.0%
(30/30)	33.5 ± 1.3
(3.9%)	100.0%
(90/90)	34.1 ± 0.99
(2.9%)
UTM
(NTC)	0.0%
(0/30)	0.0 ± 0.00
(N/A)	0.0%
(0/30)	0.0 ± 0.00
(N/A)	0.0%
(0/30)	0.0 ± 0.00
(N/A)	0.0%
(0/90)	0.0 ± 0.00
(N/A)
PC	100.0%
(30/30)	30.2 ± 0.74
(2.5%)	100.0%
(30/30)	30.4 ± 0.59
(1.9%)	100.0%
(30/30)	29.7 ± 0.86
(2.9%)	100.0%
(90/90)	30.1 ± 0.79
(2.6%)

--- Page 6 ---
could be found in cutaneous and mucocutaneous lesion swab specimens. Analytical
specificity/cross-reactivity was tested with ninety-nine (99) different bacteria, viruses, parasites
and fungi and assayed in triplicate. No cross-reactivity was observed with the ninety-nine (99)
organisms. The organisms and the concentration at which these were tested are presented in
Table 2.
Table 2. Simplexa VZV Swab Direct Cross-Reactivity
Organism Tested Concentration Organism Tested Concentration
Acholeplasma laidlawi
1 x 106 copies/mL Human genomic DNA 1 x 106 copies/mL
(genomic DNA)
Acinetobacter Human metapneumovirus
1 x 106 CFU/mL 1 x 105 TCID /mL
calcoaceticus A1 50
Human Papilloma Virus
Acinetobacter lwoffi 1 x 106 CFU/mL 1 x 105 copies/mL
18
Influenza
Adenovirus 7A 1 x 105 TCID /mL 1 x 105 TCID /mL
50 A/California/7/2009 50
Influenza
Bacteroides fragilis 1 x 106 CFU/mL 1 x 105 TCID /mL
B/Florida/02/2006 50
Bordetella bronchiseptica 1 x 106 CFU/mL Klebsiella pneumoniae 1 x 106 CFU/mL
Bordetella pertussis 1 x 106 CFU/mL Lactobacillus acidophilus 1 x 106 CFU/mL
Borrelia burgdorferi
1 x 106 copies/mL Legionella pneumophila 1 x 106 CFU/mL
(genomic DNA)
Candida albicans 1 x 106 CFU/mL Measles virus 1 x 105 TCID /mL
50
Candida glabrata 1 x 106 CFU/mL Mobiluncus curtisii 1 x 106 CFU/mL
Candida guilliermondii 1 x 106 CFU/mL Mobiluncus mulieris 1 x 106 CFU/mL
Candida krusei 1 x 106 CFU/mL Moraxella cartarrhalis 1 x 106 CFU/mL
Candida lusitaniae 1 x 106 CFU/mL Mumps virus 1 x 105 TCID /mL
50
Candida parapsilosis 1 x 106 CFU/mL Mycoplasma genitalium 1 x 106 CCU/mL
Candida tropicalis 1 x 106 CFU/mL Mycoplasma hominis 1 x 106 CCU/mL
Chlamydia trachomatis 1 x 106 IFU/mL Mycoplasma hyorhinis 1 x 106 CCU/mL
Chlamydophila
1 x 106 IFU/mL Mycoplasma orale 1 x 106 CCU/mL
pneumoniae
Clostridium difficile 1 x 106 CFU/mL Mycoplasma pneumoniae 1 x 106 CCU/mL
Clostridium perfringens 1 x 106 CFU/mL Mycoplasma salivarium 1 x 106 CCU/mL
Clostridium sordellii 1 x 106 CFU/mL Neisseria gonorrhoeae 1 x 106 CFU/mL
Coronavirus OC43 1 x 105 TCID /mL Neisseria meningitidis 1 x 106 CFU/mL
50
Corynebacterium
1 x 106 CFU/mL Parainfluenza Type 1 1 x 105 TCID /mL
diphtheriae 50
Corynebacterium
1 x 106 CFU/mL Parainfluenza Type 2 1 x 105 TCID /mL
genitalium 50
Coxsackievirus B1 1 x 105 TCID /mL Parainfluenza Type 3 1 x 105 TCID /mL
50 50
Coxsackievirus B4 1 x 105 TCID /mL Parainfluenza Type 4 1 x 105 TCID /mL
50 50
Cytomegalovirus (AD169 Prevotella
1 x 105 TCID /mL 1 x 106 CFU/mL
strain) 50 melaninogenica
K192376 - Page 6 of 16

[Table 1 on page 6]
Organism	Tested Concentration	Organism	Tested Concentration
Acholeplasma laidlawi
(genomic DNA)	1 x 106 copies/mL	Human genomic DNA	1 x 106 copies/mL
Acinetobacter
calcoaceticus	1 x 106 CFU/mL	Human metapneumovirus
A1	1 x 105 TCID /mL
50
Acinetobacter lwoffi	1 x 106 CFU/mL	Human Papilloma Virus
18	1 x 105 copies/mL
Adenovirus 7A	1 x 105 TCID /mL
50	Influenza
A/California/7/2009	1 x 105 TCID /mL
50
Bacteroides fragilis	1 x 106 CFU/mL	Influenza
B/Florida/02/2006	1 x 105 TCID /mL
50
Bordetella bronchiseptica	1 x 106 CFU/mL	Klebsiella pneumoniae	1 x 106 CFU/mL
Bordetella pertussis	1 x 106 CFU/mL	Lactobacillus acidophilus	1 x 106 CFU/mL
Borrelia burgdorferi
(genomic DNA)	1 x 106 copies/mL	Legionella pneumophila	1 x 106 CFU/mL
Candida albicans	1 x 106 CFU/mL	Measles virus	1 x 105 TCID /mL
50
Candida glabrata	1 x 106 CFU/mL	Mobiluncus curtisii	1 x 106 CFU/mL
Candida guilliermondii	1 x 106 CFU/mL	Mobiluncus mulieris	1 x 106 CFU/mL
Candida krusei	1 x 106 CFU/mL	Moraxella cartarrhalis	1 x 106 CFU/mL
Candida lusitaniae	1 x 106 CFU/mL	Mumps virus	1 x 105 TCID /mL
50
Candida parapsilosis	1 x 106 CFU/mL	Mycoplasma genitalium	1 x 106 CCU/mL
Candida tropicalis	1 x 106 CFU/mL	Mycoplasma hominis	1 x 106 CCU/mL
Chlamydia trachomatis	1 x 106 IFU/mL	Mycoplasma hyorhinis	1 x 106 CCU/mL
Chlamydophila
pneumoniae	1 x 106 IFU/mL	Mycoplasma orale	1 x 106 CCU/mL
Clostridium difficile	1 x 106 CFU/mL	Mycoplasma pneumoniae	1 x 106 CCU/mL
Clostridium perfringens	1 x 106 CFU/mL	Mycoplasma salivarium	1 x 106 CCU/mL
Clostridium sordellii	1 x 106 CFU/mL	Neisseria gonorrhoeae	1 x 106 CFU/mL
Coronavirus OC43	1 x 105 TCID /mL
50	Neisseria meningitidis	1 x 106 CFU/mL
Corynebacterium
diphtheriae	1 x 106 CFU/mL	Parainfluenza Type 1	1 x 105 TCID /mL
50
Corynebacterium
genitalium	1 x 106 CFU/mL	Parainfluenza Type 2	1 x 105 TCID /mL
50
Coxsackievirus B1	1 x 105 TCID /mL
50	Parainfluenza Type 3	1 x 105 TCID /mL
50
Coxsackievirus B4	1 x 105 TCID /mL
50	Parainfluenza Type 4	1 x 105 TCID /mL
50
Cytomegalovirus (AD169
strain)	1 x 105 TCID /mL
50	Prevotella
melaninogenica	1 x 106 CFU/mL

--- Page 7 ---
Organism Tested Concentration Organism Tested Concentration
Cytomegalovirus (Towne
1 x 105 TCID /mL Proteus mirabilis 1 x 106 CFU/mL
strain) 50
Echovirus 11 1 x 105 TCID /mL Proteus vulgaris 1 x 106 CFU/mL
50
Enterobacter cloacae 1 x 106 CFU/mL Pseudomonas aeruginosa 1 x 106 CFU/mL
Enterococcus faecalis
1 x 106 CFU/mL RSV A Long 1 x 105 TCID /mL
vanB 50
Enterococcus faecium 1 x 106 CFU/mL RSV B Washington 1 x 105 TCID /mL
50
Enterovirus 70 1 x 105 TCID /mL Rubella Virus 1 x 105 TCID /mL
50 50
Salmonella enteritidis
Enterovirus 71 1 x 105 TCID /mL 1 x 106 copies/mL
50 (genomic DNA)
Epstein Barr Virus (B95-
1 x 105 copies/mL Salmonella typhimurium 1 x 106 CFU/mL
8 strain)
Escherichia coli O15:H7 1 x 106 CFU/mL Serratia marcescens 1 x 106 CFU/mL
Fusobacterium nucleatum 1 x 106 CFU/mL Simian Virus type 40 1 x 105 TCID /mL
50
Staphylococcus aureus
Gardnerella vaginalis 1 x 106 CFU/mL 1 x 106 CFU/mL
(MRSA), ATCC 700699
Staphylococcus aureus
Haemophilus ducreyi 1 x 106 CFU/mL 1 x 106 CFU/mL
(MRSA), COL
Staphylococcus
Haemophilus influenza
1 x 106 CFU/mL epidermidis (MRSE), 1 x 106 CFU/mL
type A
ATCC 29887
Staphylococcus
Hepatitis A virus 1 x 106 TCID /mL 1 x 106 CFU/mL
50 saprophyticus
Hepatitis B virus 1 x 105 IU/mL Streptococcus agalactiae 1 x 106 CFU/mL
Hepatitis C virus 1 x 105 IU/mL Streptococcus mitis 1 x 106 CFU/mL
HHV-6 (Z29 strain) 1 x 105 copies/mL Streptococcus mutans 1 x 106 CFU/mL
Streptococcus
HHV-6A 1 x 105 copies/mL 1 x 106 CFU/mL
pneumoniae
Streptococcus pyogenes,
HHV-7 SB 1 x 105 TCID /mL 1 x 106 CFU/mL
50 M1
HHV-8 1 x 105 copies/mL Streptococcus salivarius 1 x 106 CFU/mL
HIV-1 IIIB 1 x 105 TCID /mL Toxoplasma gondii 1 x 106 tachyzoites/mL
50
HIV-2 NIHZ 1 x 105 TCID /mL Trichomonas vaginalis 1 x 106 trophozoites/mL
50
HSV-1 (McIntyre strain) 1 x 105 TCID /mL Ureaplasma urealyticum 1 x 106 CCU/mL
50
HSV-2 (G strain) 1 x 105 TCID /mL
50
Note: Bacteroides ureolyticus, Hepatitis D virus, Treponema pallidum and Tropheryma whipplei
were tested using in silico NCBI BLAST analysis due to unavailability of the organism. No
cross-reactivity was found.
K192376 - Page 7 of 16

[Table 1 on page 7]
Organism	Tested Concentration	Organism	Tested Concentration
Cytomegalovirus (Towne
strain)	1 x 105 TCID /mL
50	Proteus mirabilis	1 x 106 CFU/mL
Echovirus 11	1 x 105 TCID /mL
50	Proteus vulgaris	1 x 106 CFU/mL
Enterobacter cloacae	1 x 106 CFU/mL	Pseudomonas aeruginosa	1 x 106 CFU/mL
Enterococcus faecalis
vanB	1 x 106 CFU/mL	RSV A Long	1 x 105 TCID /mL
50
Enterococcus faecium	1 x 106 CFU/mL	RSV B Washington	1 x 105 TCID /mL
50
Enterovirus 70	1 x 105 TCID /mL
50	Rubella Virus	1 x 105 TCID /mL
50
Enterovirus 71	1 x 105 TCID /mL
50	Salmonella enteritidis
(genomic DNA)	1 x 106 copies/mL
Epstein Barr Virus (B95-
8 strain)	1 x 105 copies/mL	Salmonella typhimurium	1 x 106 CFU/mL
Escherichia coli O15:H7	1 x 106 CFU/mL	Serratia marcescens	1 x 106 CFU/mL
Fusobacterium nucleatum	1 x 106 CFU/mL	Simian Virus type 40	1 x 105 TCID /mL
50
Gardnerella vaginalis	1 x 106 CFU/mL	Staphylococcus aureus
(MRSA), ATCC 700699	1 x 106 CFU/mL
Haemophilus ducreyi	1 x 106 CFU/mL	Staphylococcus aureus
(MRSA), COL	1 x 106 CFU/mL
Haemophilus influenza
type A	1 x 106 CFU/mL	Staphylococcus
epidermidis (MRSE),
ATCC 29887	1 x 106 CFU/mL
Hepatitis A virus	1 x 106 TCID /mL
50	Staphylococcus
saprophyticus	1 x 106 CFU/mL
Hepatitis B virus	1 x 105 IU/mL	Streptococcus agalactiae	1 x 106 CFU/mL
Hepatitis C virus	1 x 105 IU/mL	Streptococcus mitis	1 x 106 CFU/mL
HHV-6 (Z29 strain)	1 x 105 copies/mL	Streptococcus mutans	1 x 106 CFU/mL
HHV-6A	1 x 105 copies/mL	Streptococcus
pneumoniae	1 x 106 CFU/mL
HHV-7 SB	1 x 105 TCID /mL
50	Streptococcus pyogenes,
M1	1 x 106 CFU/mL
HHV-8	1 x 105 copies/mL	Streptococcus salivarius	1 x 106 CFU/mL
HIV-1 IIIB	1 x 105 TCID /mL
50	Toxoplasma gondii	1 x 106 tachyzoites/mL
HIV-2 NIHZ	1 x 105 TCID /mL
50	Trichomonas vaginalis	1 x 106 trophozoites/mL
HSV-1 (McIntyre strain)	1 x 105 TCID /mL
50	Ureaplasma urealyticum	1 x 106 CCU/mL
HSV-2 (G strain)	1 x 105 TCID /mL
50		

--- Page 8 ---
Inhibition by other Microorganisms: The Simplexa VZV Swab Direct assay was evaluated
by testing the ability to identify VZV virus (Ellen and 9939 strains) when other potentially
inhibitory organisms are present. A panel of ninety-nine (99) potential inhibitory organisms was
individually spiked into pooled cutaneous and mucocutaneous swab matrix containing a low
concentration of VZV at approximately 2X LoD and tested in triplicate. Table below references
the microorganisms and their respective tested concentration. No inhibition was observed for the
detection of either VZV Ellen or 9939 strain.
Table 3. Simplexa VZV Swab Direct Microbial Inhibition
Organism Tested Concentration Organism Tested Concentration
Acholeplasma laidlawi
1 x 106 copies/mL Human genomic DNA 1 x 106 copies/mL
(genomic DNA)
Acinetobacter Human metapneumovirus
1 x 106 CFU/mL 1 x 105 TCID /mL
calcoaceticus A1 50
Acinetobacter lwoffi 1 x 106 CFU/mL Human papilloma virus 18 1 x 105 copies/mL
Influenza
Adenovirus 7A 1 x 105 TCID /mL 1 x 105 TCID /mL
50 A/California/7/2009 50
Influenza
Bacteroides fragilis 1 x 106 CFU/mL 1 x 105 TCID /mL
B/Florida/02/2006 50
Bordetella bronchiseptica 1 x 106 CFU/mL Klebsiella pneumoniae 1 x 106 CFU/mL
Bordetella pertussis 1 x 106 CFU/mL Lactobacillus acidophilus 1 x 106 CFU/mL
Borrelia burgdorferi
1 x 106 copies/mL Legionella pneumophila 1 x 106 CFU/mL
(genomic DNA)
Candida albicans 1 x 106 CFU/mL Measles virus 1 x 105 TCID /mL
50
Candida glabrata 1 x 106 CFU/mL Mobiluncus curtisii 1 x 106 CFU/mL
Candida guilliermondii 1 x 106 CFU/mL Mobiluncus mulieris 1 x 106 CFU/mL
Candida krusei 1 x 106 CFU/mL Moraxella cartarrhalis 1 x 106 CFU/mL
Candida lusitaniae 1 x 106 CFU/mL Mumps virus 1 x 105 TCID /mL
50
Candida parapsilosis 1 x 106 CFU/mL Mycoplasma genitalium 1 x 106 CCU/mL
Candida tropicalis 1 x 106 CFU/mL Mycoplasma hominis 1 x 106 CCU/mL
Chlamydia trachomatis 1 x 106 IFU/mL Mycoplasma hyorhinis 1 x 106 CCU/mL
Chlamydophila
1 x 106 IFU/mL Mycoplasma orale 1 x 106 CCU/mL
pneumoniae
Clostridium difficile 1 x 106 CFU/mL Mycoplasma pneumoniae 1 x 106 CCU/mL
Clostridium perfringens 1 x 106 CFU/mL Mycoplasma salivarium 1 x 106 CCU/mL
Clostridium sordellii 1 x 106 CFU/mL Neisseria gonorrhoeae 1 x 106 CFU/mL
Coronavirus OC43 1 x 105 TCID /mL Neisseria meningitidis 1 x 106 CFU/mL
50
Corynebacterium
1 x 106 CFU/mL Parainfluenza Type 1 1 x 105 TCID /mL
diphtheriae 50
Corynebacterium
1 x 106 CFU/mL Parainfluenza Type 2 1 x 105 TCID /mL
genitalium 50
Coxsackievirus B1 1 x 105 TCID /mL Parainfluenza Type 3 1 x 105 TCID /mL
50 50
Coxsackievirus B4 1 x 105 TCID /mL Parainfluenza Type 4 1 x 105 TCID /mL
50 50
Cytomegalovirus (AD169
1 x 105 TCID /mL Prevotella melaninogenica 1 x 106 CFU/mL
strain) 50
K192376 - Page 8 of 16

[Table 1 on page 8]
Organism	Tested Concentration	Organism	Tested Concentration
Acholeplasma laidlawi
(genomic DNA)	1 x 106 copies/mL	Human genomic DNA	1 x 106 copies/mL
Acinetobacter
calcoaceticus	1 x 106 CFU/mL	Human metapneumovirus
A1	1 x 105 TCID /mL
50
Acinetobacter lwoffi	1 x 106 CFU/mL	Human papilloma virus 18	1 x 105 copies/mL
Adenovirus 7A	1 x 105 TCID /mL
50	Influenza
A/California/7/2009	1 x 105 TCID /mL
50
Bacteroides fragilis	1 x 106 CFU/mL	Influenza
B/Florida/02/2006	1 x 105 TCID /mL
50
Bordetella bronchiseptica	1 x 106 CFU/mL	Klebsiella pneumoniae	1 x 106 CFU/mL
Bordetella pertussis	1 x 106 CFU/mL	Lactobacillus acidophilus	1 x 106 CFU/mL
Borrelia burgdorferi
(genomic DNA)	1 x 106 copies/mL	Legionella pneumophila	1 x 106 CFU/mL
Candida albicans	1 x 106 CFU/mL	Measles virus	1 x 105 TCID /mL
50
Candida glabrata	1 x 106 CFU/mL	Mobiluncus curtisii	1 x 106 CFU/mL
Candida guilliermondii	1 x 106 CFU/mL	Mobiluncus mulieris	1 x 106 CFU/mL
Candida krusei	1 x 106 CFU/mL	Moraxella cartarrhalis	1 x 106 CFU/mL
Candida lusitaniae	1 x 106 CFU/mL	Mumps virus	1 x 105 TCID /mL
50
Candida parapsilosis	1 x 106 CFU/mL	Mycoplasma genitalium	1 x 106 CCU/mL
Candida tropicalis	1 x 106 CFU/mL	Mycoplasma hominis	1 x 106 CCU/mL
Chlamydia trachomatis	1 x 106 IFU/mL	Mycoplasma hyorhinis	1 x 106 CCU/mL
Chlamydophila
pneumoniae	1 x 106 IFU/mL	Mycoplasma orale	1 x 106 CCU/mL
Clostridium difficile	1 x 106 CFU/mL	Mycoplasma pneumoniae	1 x 106 CCU/mL
Clostridium perfringens	1 x 106 CFU/mL	Mycoplasma salivarium	1 x 106 CCU/mL
Clostridium sordellii	1 x 106 CFU/mL	Neisseria gonorrhoeae	1 x 106 CFU/mL
Coronavirus OC43	1 x 105 TCID /mL
50	Neisseria meningitidis	1 x 106 CFU/mL
Corynebacterium
diphtheriae	1 x 106 CFU/mL	Parainfluenza Type 1	1 x 105 TCID /mL
50
Corynebacterium
genitalium	1 x 106 CFU/mL	Parainfluenza Type 2	1 x 105 TCID /mL
50
Coxsackievirus B1	1 x 105 TCID /mL
50	Parainfluenza Type 3	1 x 105 TCID /mL
50
Coxsackievirus B4	1 x 105 TCID /mL
50	Parainfluenza Type 4	1 x 105 TCID /mL
50
Cytomegalovirus (AD169
strain)	1 x 105 TCID /mL
50	Prevotella melaninogenica	1 x 106 CFU/mL

--- Page 9 ---
Organism Tested Concentration Organism Tested Concentration
Cytomegalovirus (Towne
1 x 105 TCID /mL Proteus mirabilis 1 x 106 CFU/mL
strain) 50
Echovirus 11 1 x 105 TCID /mL Proteus vulgaris 1 x 106 CFU/mL
50
Enterobacter cloacae 1 x 106 CFU/mL Pseudomonas aeruginosa 1 x 106 CFU/mL
Enterococcus faecalis
1 x 106 CFU/mL RSV A Long 1 x 105 TCID /mL
vanB 50
Enterococcus faecium 1 x 106 CFU/mL RSV B Washington 1 x 105 TCID /mL
50
Enterovirus 70 1 x 105 TCID /mL Rubella Virus 1 x 105 TCID /mL
50 50
Salmonella enteritidis
Enterovirus 71 1 x 105 TCID /mL 1 x 106 copies/mL
50 (genomic DNA)
Epstein Barr Virus (B95-8
1 x 105 copies/mL Salmonella typhimurium 1 x 106 CFU/mL
strain)
Escherichia coli O15:H7 1 x 106 CFU/mL Serratia marcescens 1 x 106 CFU/mL
Fusobacterium nucleatum 1 x 106 CFU/mL Simian Virus type 40 1 x 105 TCID /mL
50
Staphylococcus aureus
Gardnerella vaginalis 1 x 106 CFU/mL 1 x 106 CFU/mL
(MRSA), ATCC 700699
Staphylococcus aureus
Haemophilus ducreyi 1 x 106 CFU/mL 1 x 106 CFU/mL
(MRSA), COL
Staphylococcus
Haemophilus influenza
1 x 106 CFU/mL epidermidis (MRSE), 1 x 106 CFU/mL
type A
ATCC 29887
Staphylococcus
Hepatitis A virus 1 x 106 TCID /mL 1 x 106 CFU/mL
50 saprophyticus
Hepatitis B virus 1 x 105 IU/mL Streptococcus agalactiae 1 x 106 CFU/mL
Hepatitis C virus 1 x 105 IU/mL Streptococcus mitis 1 x 106 CFU/mL
HHV-6 (Z29 strain) 1 x 105 copies/mL Streptococcus mutans 1 x 106 CFU/mL
HHV-6A 1 x 105 copies/mL Streptococcus pneumoniae 1 x 106 CFU/mL
Streptococcus pyogenes,
HHV-7 SB 1 x 105 TCID /mL 1 x 106 CFU/mL
50 M1
HHV-8 1 x 105 copies/mL Streptococcus salivarius 1 x 106 CFU/mL
HIV-1 IIIB 1 x 105 TCID /mL Toxoplasma gondii 1 x 106 tachyzoites/mL
50
HIV-2 NIHZ 1 x 105 TCID /mL Trichomonas vaginalis 1 x 106 trophozoites/mL
50
HSV-1 (McIntyre strain) 1 x 105 TCID /mL Ureaplasma urealyticum 1 x 106 CCU/mL
50
HSV-2 (G strain) 1 x 105 TCID /mL
50
Note: Bacteroides ureolyticus, Hepatitis D virus, Treponema pallidum and Tropheryma whipplei were tested
using in silico NCBI BLAST analysis due to unavailability of the organism. No interference was found.
Interference: The performance of the Simplexa VZV Swab Direct assay was evaluated with
potentially interfering substances. The tested concentrations of the potential interfering
endogenous and exogenous substances are indicated in the table below. A total of forty-five
K192376 - Page 9 of 16

[Table 1 on page 9]
Organism	Tested Concentration	Organism	Tested Concentration
Cytomegalovirus (Towne
strain)	1 x 105 TCID /mL
50	Proteus mirabilis	1 x 106 CFU/mL
Echovirus 11	1 x 105 TCID /mL
50	Proteus vulgaris	1 x 106 CFU/mL
Enterobacter cloacae	1 x 106 CFU/mL	Pseudomonas aeruginosa	1 x 106 CFU/mL
Enterococcus faecalis
vanB	1 x 106 CFU/mL	RSV A Long	1 x 105 TCID /mL
50
Enterococcus faecium	1 x 106 CFU/mL	RSV B Washington	1 x 105 TCID /mL
50
Enterovirus 70	1 x 105 TCID /mL
50	Rubella Virus	1 x 105 TCID /mL
50
Enterovirus 71	1 x 105 TCID /mL
50	Salmonella enteritidis
(genomic DNA)	1 x 106 copies/mL
Epstein Barr Virus (B95-8
strain)	1 x 105 copies/mL	Salmonella typhimurium	1 x 106 CFU/mL
Escherichia coli O15:H7	1 x 106 CFU/mL	Serratia marcescens	1 x 106 CFU/mL
Fusobacterium nucleatum	1 x 106 CFU/mL	Simian Virus type 40	1 x 105 TCID /mL
50
Gardnerella vaginalis	1 x 106 CFU/mL	Staphylococcus aureus
(MRSA), ATCC 700699	1 x 106 CFU/mL
Haemophilus ducreyi	1 x 106 CFU/mL	Staphylococcus aureus
(MRSA), COL	1 x 106 CFU/mL
Haemophilus influenza
type A	1 x 106 CFU/mL	Staphylococcus
epidermidis (MRSE),
ATCC 29887	1 x 106 CFU/mL
Hepatitis A virus	1 x 106 TCID /mL
50	Staphylococcus
saprophyticus	1 x 106 CFU/mL
Hepatitis B virus	1 x 105 IU/mL	Streptococcus agalactiae	1 x 106 CFU/mL
Hepatitis C virus	1 x 105 IU/mL	Streptococcus mitis	1 x 106 CFU/mL
HHV-6 (Z29 strain)	1 x 105 copies/mL	Streptococcus mutans	1 x 106 CFU/mL
HHV-6A	1 x 105 copies/mL	Streptococcus pneumoniae	1 x 106 CFU/mL
HHV-7 SB	1 x 105 TCID /mL
50	Streptococcus pyogenes,
M1	1 x 106 CFU/mL
HHV-8	1 x 105 copies/mL	Streptococcus salivarius	1 x 106 CFU/mL
HIV-1 IIIB	1 x 105 TCID /mL
50	Toxoplasma gondii	1 x 106 tachyzoites/mL
HIV-2 NIHZ	1 x 105 TCID /mL
50	Trichomonas vaginalis	1 x 106 trophozoites/mL
HSV-1 (McIntyre strain)	1 x 105 TCID /mL
50	Ureaplasma urealyticum	1 x 106 CCU/mL
HSV-2 (G strain)	1 x 105 TCID /mL
50		

--- Page 10 ---
(45) potential interfering substances were individually spiked into a pooled cutaneous and
mucocutaneous swab matrix containing a low concentration of VZV at approximately 2X LoD
and tested in triplicate. No interference was observed as shown below.
Table 4. Simplexa VZV Swab Direct Interference
Potentially Interfering Tested # Detected/
VZV Strain Active Ingredient
Substance. Concentration # Tested
9939 3/3
Abreva Docosanol 10% 7% (w/v)
Ellen 3/3
9939 3/3
Acetaminophen N/A 7% (w/v)
Ellen 3/3
9939 3/3
Acyclovir N/A 10 mg/mL
Ellen 3/3
9939 3/3
Albumin N/A 10 mg/mL
Ellen 3/3
9939 Buffers, emulsifiers, PEG, 3/3
Balneol lotion water, mineral oil, lanolin oil, 7% (v/v)
Ellen 3/3
preservatives
9939 3/3
Carmex Camphor, 1.7%; Menthol, 0.7% 10% (w/v)
Ellen 3/3
9939 3/3
Casein N/A 10 mg/mL
Ellen 3/3
9939 3/3
Chlor-Trimeton Chlorpheniramine maleate 5 mg/mL
Ellen 3/3
9939 3/3
Cidofovir N/A 2.5 mg/mL
Ellen 3/3
Clotrimazole Vaginal 9939 7% (w/v) 3/3
Clotrimazole
Cream Ellen 3.5% (w/v) 3/3
Ellen 5% (w/v) 3/3
Cold-Eeze Zincum Gluconicum 2X
9939 2.5% (w/v) 3/3
9939 3/3
Cornstarch N/A 1.25 mg/mL
Ellen 3/3
9939 3/3
Denavir N/A 2.5 mg/mL
Ellen 3/3
7% (w/v) 2/2
9939
Desitin Zinc Oxide, 40% 3.5% (w/v) 3/3
Ellen 3.5% (w/v) 3/3
Dextromethorphan 9939 3/3
Dextromethorphan
hydrobromide 10 mg/mL
Ellen hydrobromide 3/3
(Robitussin-DM)
9939 3/3
Douche N/A 7% (v/v)
Ellen 3/3
9939 3/3
Famciclovir N/A 2.5 mg/mL
Ellen 3/3
9939 3/3
Feces N/A 2.5 mg/mL
Ellen 3/3
9939 3/3
Foscarnet N/A 1.25 mg/mL
Ellen 3/3
9939 3/3
Glucose N/A 11 mg/mL
Ellen 3/3
Gynol II contraceptive 9939 3/3
Nonoxynol-9 (3%) 7% (w/v)
jelly Ellen 3/3
Human genomic DNA 9939 N/A 20 µg/mL 3/3
K192376 - Page 10 of 16

[Table 1 on page 10]
	Potentially Interfering		VZV Strain	Active Ingredient		Tested			# Detected/	
	Substance.					Concentration			# Tested	
Abreva			9939	Docosanol 10%	7% (w/v)			3/3		
			Ellen					3/3		
Acetaminophen			9939	N/A	7% (w/v)			3/3		
			Ellen					3/3		
Acyclovir			9939	N/A	10 mg/mL			3/3		
			Ellen					3/3		
Albumin			9939	N/A	10 mg/mL			3/3		
			Ellen					3/3		
Balneol lotion			9939	Buffers, emulsifiers, PEG,
water, mineral oil, lanolin oil,
preservatives	7% (v/v)			3/3		
			Ellen					3/3		
Carmex			9939	Camphor, 1.7%; Menthol, 0.7%	10% (w/v)			3/3		
			Ellen					3/3		
Casein			9939	N/A	10 mg/mL			3/3		
			Ellen					3/3		
Chlor-Trimeton			9939	Chlorpheniramine maleate	5 mg/mL			3/3		
			Ellen					3/3		
Cidofovir			9939	N/A	2.5 mg/mL			3/3		
			Ellen					3/3		
Clotrimazole Vaginal
Cream			9939	Clotrimazole	7% (w/v)			3/3		
			Ellen		3.5% (w/v)			3/3		
Cold-Eeze			Ellen	Zincum Gluconicum 2X	5% (w/v)			3/3		
			9939		2.5% (w/v)			3/3		
Cornstarch			9939	N/A	1.25 mg/mL			3/3		
			Ellen					3/3		
Denavir			9939	N/A	2.5 mg/mL			3/3		
			Ellen					3/3		
Desitin			9939	Zinc Oxide, 40%	7% (w/v)			2/2		
					3.5% (w/v)			3/3		
			Ellen		3.5% (w/v)			3/3		
Dextromethorphan
hydrobromide
(Robitussin-DM)			9939	Dextromethorphan
hydrobromide	10 mg/mL			3/3		
			Ellen					3/3		
Douche			9939	N/A	7% (v/v)			3/3		
			Ellen					3/3		
Famciclovir			9939	N/A	2.5 mg/mL			3/3		
			Ellen					3/3		
Feces			9939	N/A	2.5 mg/mL			3/3		
			Ellen					3/3		
Foscarnet			9939	N/A	1.25 mg/mL			3/3		
			Ellen					3/3		
Glucose			9939	N/A	11 mg/mL			3/3		
			Ellen					3/3		
Gynol II contraceptive
jelly			9939	Nonoxynol-9 (3%)	7% (w/v)			3/3		
			Ellen					3/3		
Human genomic DNA			9939	N/A	20 µg/mL			3/3		

--- Page 11 ---
Potentially Interfering Tested # Detected/
VZV Strain Active Ingredient
Substance. Concentration # Tested
Ellen 3/3
9939 3/3
Immunoglobulin N/A 10 mg/mL
Ellen 3/3
9939 10 mg/mL 3/3
KY Jelly N/A
Ellen 5% (w/v) 3/3
9939 3/3
Lactate N/A 2.2 mg/mL
Ellen 3/3
9939 Benzethonium chloride, 0.2%; 3/3
Lanacane 7% (v/v)
Ellen Benzocaine, 20% 3/3
9939 7% (w/v) 3/3
Lip-Clear Lysine Zinc Oxide, 1.2%
Ellen 3.5% (w/v) 3/3
9939 3/3
Miconazole 1 Miconazole nitrate, 26% 10% (w/v)
Ellen 3/3
9939 3/3
Miconazole 3 Miconazole nitrate, 2% 10% (w/v)
Ellen 3/3
9939 3/3
Monistat 1 insert Miconazole nitrate, 1200 mg 7% (w/v)
Ellen 3/3
9939 3/3
Monistat 3 cream Miconazole nitrate 2% 7% (w/v)
Ellen 3/3
9939 Eucalyptol, 0.092%; Menthol, 3/3
Mouthwash (Listerine) 0.042%; Methyl salicylate, 7% (v/v)
Ellen 3/3
0.060%; Thymol, 0.064%
9939 3/3
Mucin N/A 5% (w/v)
Ellen 3/3
9939 3/3
Preparation H N/A 10% (w/v)
Ellen 3/3
9939 3/3
Releev N/A 10% (w/v)
Ellen 3/3
9939 3/3
Seminal Fluid N/A 10% (v/v)
Ellen 3/3
9939 3/3
Tioconazole 1 N/A 10% (w/v)
Ellen 3/3
9939 3/3
Toothpaste (Colgate) Sodium fluoride, 0.243% 7% (w/v)
Ellen 3/3
9939 3/3
Urine N/A 10% (v/v)
Ellen 3/3
9939 Benzocaine (5%), Resorcinol 3/3
Vagisil creme 7% (w/v)
Ellen (2%) 3/3
9939 3/3
Valacyclovir N/A 2.5 mg/mL
Ellen 3/3
9939 3/3
Valgancyclovir N/A 2.5 mg/mL
Ellen 3/3
9939 3/3
White blood cells N/A 5.5x107 cells/mL
Ellen 3/3
9939 3/3
Whole Blood in EDTA N/A 10% (v/v)
Ellen 3/3
9939 Candida albicans 27X HPU 3/3
(Candida albicans), Candida
parapsilosis 27X HPUS
YeastGard suppositories 7% (w/v)
(Candida parapsilosis),
Ellen 3/3
Pulsatilla 27X HPUS (Meadow
Anemone)
K192376 - Page 11 of 16

[Table 1 on page 11]
	Potentially Interfering		VZV Strain	Active Ingredient		Tested			# Detected/	
	Substance.					Concentration			# Tested	
			Ellen					3/3		
Immunoglobulin			9939	N/A	10 mg/mL			3/3		
			Ellen					3/3		
KY Jelly			9939	N/A	10 mg/mL			3/3		
			Ellen		5% (w/v)			3/3		
Lactate			9939	N/A	2.2 mg/mL			3/3		
			Ellen					3/3		
Lanacane			9939	Benzethonium chloride, 0.2%;
Benzocaine, 20%	7% (v/v)			3/3		
			Ellen					3/3		
Lip-Clear Lysine			9939	Zinc Oxide, 1.2%	7% (w/v)			3/3		
			Ellen		3.5% (w/v)			3/3		
Miconazole 1			9939	Miconazole nitrate, 26%	10% (w/v)			3/3		
			Ellen					3/3		
Miconazole 3			9939	Miconazole nitrate, 2%	10% (w/v)			3/3		
			Ellen					3/3		
Monistat 1 insert			9939	Miconazole nitrate, 1200 mg	7% (w/v)			3/3		
			Ellen					3/3		
Monistat 3 cream			9939	Miconazole nitrate 2%	7% (w/v)			3/3		
			Ellen					3/3		
Mouthwash (Listerine)			9939	Eucalyptol, 0.092%; Menthol,
0.042%; Methyl salicylate,
0.060%; Thymol, 0.064%	7% (v/v)			3/3		
			Ellen					3/3		
Mucin			9939	N/A	5% (w/v)			3/3		
			Ellen					3/3		
Preparation H			9939	N/A	10% (w/v)			3/3		
			Ellen					3/3		
Releev			9939	N/A	10% (w/v)			3/3		
			Ellen					3/3		
Seminal Fluid			9939	N/A	10% (v/v)			3/3		
			Ellen					3/3		
Tioconazole 1			9939	N/A	10% (w/v)			3/3		
			Ellen					3/3		
Toothpaste (Colgate)			9939	Sodium fluoride, 0.243%	7% (w/v)			3/3		
			Ellen					3/3		
Urine			9939	N/A	10% (v/v)			3/3		
			Ellen					3/3		
Vagisil creme			9939	Benzocaine (5%), Resorcinol
(2%)	7% (w/v)			3/3		
			Ellen					3/3		
Valacyclovir			9939	N/A	2.5 mg/mL			3/3		
			Ellen					3/3		
Valgancyclovir			9939	N/A	2.5 mg/mL			3/3		
			Ellen					3/3		
White blood cells			9939	N/A	5.5x107 cells/mL			3/3		
			Ellen					3/3		
Whole Blood in EDTA			9939	N/A	10% (v/v)			3/3		
			Ellen					3/3		
YeastGard suppositories			9939	Candida albicans 27X HPU
(Candida albicans), Candida
parapsilosis 27X HPUS
(Candida parapsilosis),
Pulsatilla 27X HPUS (Meadow
Anemone)	7% (w/v)			3/3		
			Ellen					3/3		

--- Page 12 ---
4. Assay Reportable Range: N/A
5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods): N/A
6. Detection Limit:
The limit of detection (LoD) was determined for the Simplex VZV Swab Direct assay using
quantified stocks of two (2) VZV strains (Ellen and 9939) in a pool of cutaneous and
mucocutaneous lesion swab sample types UTM matrix. The LoD was determined to be the
lowest concentration that could be detected positive ≥95% of the time. The LoD for each
strain is presented in Table 5.
Table 5. Simplexa VZV Swab Direct Assay Limit of Detection
VZV Strain LoD (TCID /mL) LoD (Copies /mL)
50
993 0.77 800
Elle 0.054 3500
7. Assay Cut-Off: N/A
8. Accuracy (Instrument): N/A
9. Carry-Over:
The amplification carry-over for the Simplexa assays including the Simplexa VZV Swab
Direct was assessed from the Simplexa Flu A/B & RSV Direct viral assay study. The study
can be applied to the Simplexa VZV Swab Direct assay as the study is not analyte specific. In
the Simplexa Flu A/B & RSV Direct, the amplification carry-over study was performed to
determine the potential for contamination when negative samples are tested adjacent to
strong positive samples. The study was designed by alternately placing high positive and
negative samples on each disc. No evidence of carry-over contamination was observed.
B Comparison Studies:
1. Method Comparison with Predicate Device:
Clinical Studies
K192376 - Page 12 of 16

[Table 1 on page 12]
		
VZV Strain	LoD (TCID /mL)
50	LoD (Copies /mL)
		
993	0.77	800
Elle	0.054	3500

--- Page 13 ---
The performance of the Simplexa VZV Swab Direct assay was established in a clinical study
that included three cohorts based on sample status. Specifically, prospective and retrospective
cutaneous and mucocutaneous swab samples from human patients with signs and symptoms of
VZV infection, as well as contrived samples, were tested in the clinical agreement study.
Prospective Study: A total of four hundred fifty-two (452) cutaneous and mucocutaneous
prospective specimens were collected from ten collection sites across the USA during the clinical
study (November 2018 – May 2019). The specimens were taken from anorectal, genital, nasal,
ocular, oral, skin and urethral locations of the body. The age of the patients ranged from one
month to greater than 60 years of age. Of these specimens, 62.4% of the specimens were from
female patients and 37.6% of the specimens were from male patients. Ten testing sites performed
the Simplexa VZV Swab Direct assay on enrolled specimens and shipped the specimens to two
comparator testing sites to test against a three part composite reference method (CRM). The
three part CRM consisted of VZV direct stain fluorescent antibody (DSFA) and/or culture
isolation with direct fluorescent antibody (DFA) and two validated VZV polymerase chain
reaction (PCR) assays followed by bi-directional sequencing. The comparator testing was
performed by two sites. One testing site performed the VZV DSFA and/or culture isolation with
DFA and another testing site conducted the two validated VZV PCR assays testing followed by
bi-directional sequencing. The results of the study are presented in Table 6.
Table 6. Simplexa VZV Swab Direct Prospective Agreement Results
Composite Reference
Method (CRM)
+ -
Prospective Sensitivity Specificity
Simplexa Simplexa Total
Study 95% CIc 95% CI
VZV Swab VZV Swab
Direct Direct
+ - + -
87.5% (7/8) 100.0% (171/171)
Mucocutaneous 7 1a 0 171 179
52.9% - 97.8% 97.8% - 100.0%
98.8% (79/80) 98.2% (162/165)
Cutaneous 79 1b 3 162 245
93.3% - 99.8% 94.8% - 99.4%
100.0% (1/1) 100.0% (27/27)
Unknown 1 0 0 27 28
20.7% - 100.0% 87.5% - 100.0%
97.8% (87/89) 99.2% (360/363)
All 87 2 3 360 452
92.2% -99.4 % 97.6% - 99.7%
a The discordant negative mucocutaneous result is from an oral lesion sample. The sample was
negative by the Simplexa VZV Swab Direct, DSFA/DFA and by the sites routine culture testing.
The sample was positive by the two (2) PCR/Bi-directional sequencing assays.
b The discordant negative cutaneous result is from a skin lesion sample. The sample was negative by
the Simplexa VZV Swab Direct, DSFA/DFA testing. The sample was positive by the 2 PCR/Bi-
directional sequencing assays.
c CI = Confidence Interval. The 95% confidence intervals (CI) were calculated following Wilson
Score method.
Retrospective Study: A total of sixty (60) cutaneous and mucocutaneous retrospective positive
swab specimens in UTM were blinded and randomized with one hundred twenty (120) negative
masked specimens prior to being tested by Simplexa VZV Swab Direct assay. The Composite
Reference Method 2 (CRM 2) utilized a two out of three outcomes from one FDA Cleared
NAAT PCR assay for VZV and two validated VZV PCR assays followed by bi-directional
sequencing. The FDA Cleared NAAT was performed by one external site. DiaSorin Molecular
performed the Simplexa VZV Swab Direct testing and different DiaSorin Molecular operators
K192376 - Page 13 of 16

[Table 1 on page 13]
ocular, oral, skin and urethral locations of the body. The age of the patients ranged from one
month to greater than 60 years of age. Of these specimens, 62.4% of the specimens were from
female patients and 37.6% of the specimens were from male patients. Ten testing sites performed
the Simplexa VZV Swab Direct assay on enrolled specimens and shipped the specimens to two
comparator testing sites to test against a three part composite reference method (CRM). The
three part CRM consisted of VZV direct stain fluorescent antibody (DSFA) and/or culture
isolation with direct fluorescent antibody (DFA) and two validated VZV polymerase chain
reaction (PCR) assays followed by bi-directional sequencing. The comparator testing was
performed by two sites. One testing site performed the VZV DSFA and/or culture isolation with
DFA and another testing site conducted the two validated VZV PCR assays testing followed by
bi-directional sequencing. The results of the study are presented in

[Table 2 on page 13]
Prospective
Study		Composite Reference											Total	Sensitivity
95% CIc			Specificity
95% CI		
		Method (CRM)																	
		+						-											
		Simplexa						Simplexa											
		VZV Swab						VZV Swab											
		Direct						Direct											
		+			-			+			-								
Mucocutaneous	7			1a			0			171			179	87.5% (7/8)
52.9% - 97.8%			100.0% (171/171)
97.8% - 100.0%		
Cutaneous	79			1b			3			162			245	98.8% (79/80)
93.3% - 99.8%			98.2% (162/165)
94.8% - 99.4%		
Unknown	1			0			0			27			28	100.0% (1/1)
20.7% - 100.0%			100.0% (27/27)
87.5% - 100.0%		
All	87			2			3			360			452		97.8% (87/89)			99.2% (360/363)	
															92.2% -99.4 %			97.6% - 99.7%	

[Table 3 on page 13]
Prospective
Study

[Table 4 on page 13]
Sensitivity
95% CIc

[Table 5 on page 13]
Specificity
95% CI

--- Page 14 ---
performed the two validated VZV PCR assays followed by bi-directional sequencing. The
positive and negative percent agreement (PPA and NPA) results of the study are presented in
Table 7.
Table 7. Simplexa VZV Swab Direct Retrospective Agreement Results
Composite Reference
Method 2
(CRM 2)
PPA NPA
+ -
Retrospective Total 95% CIb 95% CI
Simplexa Simplexa
Study
VZV Swab VZV Swab
Direct Direct
+ - + -
90.0% (9/10) 100.0% (63/63)
Mucocutaneous 9 1a 0 63 73
59.6% - 98.2% 94.3% - 100.0%
100.0% (52/52) 98.2% (54/55)
Cutaneous 52 0 1 54 107
93.1% - 100.0% 90.4% - 99.7%
98.4% (61/62) 99.2% (117/118)
All 61 1 1 117 180
91.4% - 99.7% 95.4% - 99.9%
a The discordant negative mucocutaneous result is from an oral lesion sample. The sample was
negative by the Simplexa VZV Swab Direct and NAAT testing. The sample was positive by the
two (2) PCR/Bi-directional sequencing assays.
b CI = Confidence Interval. The 95% confidence intervals (CI) were calculated following
Wilson Score method.
Contrived Sample Study: A total of sixty (60) contrived positive specimens in individual
negative UTM mucocutaneous swab matrix were blinded and randomized with sixty (60) masked
negative UTM mucocutaneous specimens prior to being tested by Simplexa VZV Swab Direct
assay. The results were compared with a two out of three outcomes from one FDA Cleared
NAAT assay and two validated VZV PCR assays followed by bi-directional sequencing
(Composite Reference Method 2 or CRM 2). Of the sixty (60) contrived specimens, thirty (30)
were spiked with VZV Ellen strain and thirty (30) were spiked with VZV 9939 strain at different
known concentrations across the detection range. The results are presented in Table 8.
Table 8. Simplexa VZV Swab Direct Contrived Agreement Results
Composite Reference
Method 2
(CRM 2)
Contrived PPA NPA
+ -
Mucocutaneous Total 95% CIa 95% CI
Simplexa™ Simplexa™
Samples
VZV Swab VZV Swab
Direct Direct
+ - + -
100.0% (30/30)
Ellen 30 0 0 0 30 N/A
88.6% - 100.0%
100.0% (30/30)
9939 30 0 0 0 30 N/A
88.6% - 100.0%
60/60 (100%)
Negative 0 0 0 60 60 N/A
94.0% -100.0%
100.0% (60/60) 100.0% (60/60)
All 60 0 0 60 120
94.0% - 100.0% 94.0% - 100.0%
a CI = Confidence Interval. The 95% confidence intervals (CI) were calculated following Wilson
Score method.
K192376 - Page 14 of 16

[Table 1 on page 14]
Retrospective
Study	Composite Reference
Method 2
(CRM 2)								Total	PPA
95% CIb	NPA
95% CI
	+				-						
	Simplexa
VZV Swab
Direct				Simplexa
VZV Swab
Direct						
	+		-		+		-				
Mucocutaneous	9		1a		0		63		73	90.0% (9/10)
59.6% - 98.2%	100.0% (63/63)
94.3% - 100.0%
Cutaneous	52		0		1		54		107	100.0% (52/52)
93.1% - 100.0%	98.2% (54/55)
90.4% - 99.7%
All	61		1		1		117		180	98.4% (61/62)
91.4% - 99.7%	99.2% (117/118)
95.4% - 99.9%

[Table 2 on page 14]
Contrived
Mucocutaneous
Samples	Composite Reference
Method 2
(CRM 2)								Total	PPA
95% CIa	NPA
95% CI
	+				-						
	Simplexa™
VZV Swab
Direct				Simplexa™
VZV Swab
Direct						
	+		-		+		-				
Ellen	30		0		0		0		30	100.0% (30/30)
88.6% - 100.0%	N/A
9939	30		0		0		0		30	100.0% (30/30)
88.6% - 100.0%	N/A
Negative	0		0		0		60		60	N/A	60/60 (100%)
94.0% -100.0%
All	60		0		0		60		120	100.0% (60/60)
94.0% - 100.0%	100.0% (60/60)
94.0% - 100.0%

--- Page 15 ---
2. Matrix Comparison: N/A
C Clinical Studies:
1. Clinical Sensitivity: N/A
2. Clinical Specificity: N/A
3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):
N/A
D Clinical Cut-Off: N/A
E Expected Values/Reference Range:
In the prospective clinical study 452 cutaneous and mucocutaneous samples were tested by
Simplexa VZV Swab Direct. The values for VZV detection per site varied between 0% and 75%.
The overall expected value for all sites is 19.9%. The expected values per site are presented in
Table 9 below.
Table 9. VZV Incidence as Determined by Simplexa VZV Swab Direct
VZV Incidence
Site ID Total # Detected
% Detected
3 4 3 75.0%
5 61 24 39.9%
6 48 15 31.3%
7 38 13 34.2%
8 12 3 25.0%
9 108 1 0.9%
10 139 16 11.5%
11 28 15 53.6%
13 14 0 0.0%
Total 452 90 19.9%
F Other Supportive Instrument Performance Characteristics Data: N/A
K192376 - Page 15 of 16

[Table 1 on page 15]
Site ID	Total	# Detected		VZV Incidence	
				% Detected	
3	4	3	75.0%		
5	61	24	39.9%		
6	48	15	31.3%		
7	38	13	34.2%		
8	12	3	25.0%		
9	108	1	0.9%		
10	139	16	11.5%		
11	28	15	53.6%		
13	14	0	0.0%		
Total	452	90	19.9%		

--- Page 16 ---
VIII Proposed Labeling:
The labeling supports the finding of substantial equivalence for this device.
IX Conclusion:
The submitted information in this premarket notification is complete and supports a substantial
equivalence decision.
K192376 - Page 16 of 16